Taxotere docetaxel: Phase III data; marketed to treat locally advanced or metastatic breast cancer after failure of prior chemotherapy

In a 207-patient Phase III study, the one-year and 20-month survival rates of

Read the full 131 word article

How to gain access

Continue reading with a
two-week free trial.